Management of subclinical hyperthyroidism

International Journal of Endocrinology and Metabolism

Volumn 10, Issue 2, 2012, Pages 490-496

  Palacios, Silvia Santos ^a   Pascual Corrales, Eider ^a   Galofre, Juan Carlos ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Disease management; Graves disease; Hyperthyroidism; Therapeutics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; LEVOTHYROXINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THYROID HORMONE; THYROTROPIN;

ABLATION THERAPY; AGED HOSPITAL PATIENT; AGRANULOCYTOSIS; BONE METABOLISM; CARDIOVASCULAR DISEASE; COMORBIDITY; DEMENTIA; DEPRESSION; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EUTHYROID SICK SYNDROME; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GLOMERULONEPHRITIS; GRAVES DISEASE; HEALTH CARE NEED; HEART ATRIUM FIBRILLATION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; LIVER DISEASE; LOW DRUG DOSE; MEDICAL ASSESSMENT; MEDICAL HISTORY; MINERAL METABOLISM; OSTEOPOROSIS; PALLIATIVE THERAPY; PATIENT MONITORING; PREVALENCE; REVIEW; SIDE EFFECT; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; TOXIC GOITER; VASCULITIS;

EID: 84864001543     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.3447     Document Type: Review

References (58)

1. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99.
3. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination Survey III thyroidstimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab. 2007;92(11):4236-40.
4. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8(6):457-69.
5. Surks MI, Boucai L. Age-and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab. 2010;95(2):496-502.
6. Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21(1):5-11.
7. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13(1):3-126.
8. Fatourechi V. Upper limit of normal serum thyroid-stimulating hormone: a moving and now an aging target? J Clin Endocrinol Metab. 2007;92(12):4560-2.
9. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92(12):4575-82.
10. Galofré JC, Frühbeck G, Salvador J. Obesity and Thyroid Function: Pathophysiological and Therapeutic Implications. Hot Thyroidol. 2010.
11. Galofré JC, Payeras F, Silva C, Salvador J. Endocrine function tests. In: Prieto JM, Yuste V, Ara JR, editors. Elsevier Masson. Barcelona; 2010. p. 329-406.
12. Cooper DS. Subclinical thyroid disease: consensus or conundrum? Clin Endocrinol (Oxf). 2004;60(4):410-2.
13. de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149(3):526-32.
14. Mitchell AL, Pearce SH. How should we treat patients with low serum thyrotropin concentrations? Clin Endocrinol (Oxf). 2010;72(3):292-6.
15. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007;92(1):3-9.
16. Wartofsky L. Management of subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(1):59-61.
17. Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt). 2009;18(11):1847-56.
18. Galofre JC. [Management of subclinical hyperthyroidism]. Rev Med Univ Navarra. 2007;51(1):18-22.
19. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf). 1991;34(1):77-83.
20. Bjorndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R. Prevalence and causes of undiagnosed hyperthyroidismin an adult healthy population. The Tromso study. J Endocrinol Invest. 2008;31(10):856-60.
21. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: fiveyear follow-up in a large network of primary care physicians. Arch Intern Med. 2007;167(14):1533-8.
22. Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid. 2005;15(7):687-91.
23. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA. 2004;291(2):239-43.
24. Diez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology. 2003;49(5):316-23.
25. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol. 2006;107(2 Pt 1):337-41.
26. Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population - predictors of outcome. Clin Endocrinol (Oxf). 2011;74(2):257-61.
27. Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf). 2008;68(3):491-2.
28. Lewis GF, Alessi CA, Imperial JG, Refetoff S. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab. 1991;73(4):843-9.
29. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab. 1993;77(5):1130-4.
30. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-35.
31. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228-38.
32. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134(7):561-8.
33. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(5):1344-51.
34. Yavuz DG, Yazici D, Toprak A, Deyneli O, Aydin H, Yuksel M, et al. Exogenous subclinical hyperthyroidism impairs endothelial function in nodular goiter patients. Thyroid. 2008;18(4):395-400.
35. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76-131.
36. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88(4):1672-7.
37. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145(4):391-6.
38. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middleaged patients. J Clin Endocrinol Metab. 2000;85(12):4701-5.
39. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249-52.
40. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033-41.
41. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358(9285):861-5.
42. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832-45.
43. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008;159(3):329-41.
44. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf). 2000;53(6):733-7.
45. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med. 2006;145(8):573-81.
46. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90(1):581-5; discussion 6-7.
47. Papi G, Pearce EN, Braverman LE, Betterle C, Roti E. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med. 2005;118(4):349-61.
48. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005;152(1):1-9.
49. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001;345(7):512-6.
50. Fatourechi V. Subclinical thyroid disease. Mayo Clin Proc. 2001;76(4):413-6; quiz 6-7.
51. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-55.
52. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf). 1994;41(4):421-4.
53. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf). 1998;48(3):285-90.
54. Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract. 2008;14(8):973-8.
55. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-17.
56. Malozowski S, Chiesa A. Propylthiouracil-induced hepatotoxicity and death. Hopefully, never more. J Clin Endocrinol Metab. 2010;95(7):3161-3.
57. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360(15):1574-5.
58. Azizi F, Amouzegar A. Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol. 2011;164(6):871-6.